drugset
drugset / Trial / NCT05334810

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

NCT05334810 ↗

Phase 2 Unknown 191 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a study of DP303c in patients with HER2-positive advanced breast cancer.

Timeline

Start
2022-05-01
Primary completion
2023-12-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject TRASTUZUMAB ENVEDOTIN Monoclonal antibody 3 mg/kg —

Indications

HER2 positive breast carcinoma